[ DB00065 in aggressive and refractory rheumatoid arthritis. A pilot study ] . Rheumatoid arthritis is a chronic inflammatory disease with a progressive course , that frequently provokes permanent incapacity if not adequately treated . Rheumatoid arthritis may be not responsive to the common second line drugs . This study was aimed to treat 15 patients affected by severe refractory rheumatoid arthritis with infliximab . PATIENTS AND METHODS : Fifteen patients with refractory rheumatoid arthritis were treated with infliximab -- monoclonal antibody direct to P01375 alpha -- in association with methotrexate or azathioprine . DB00065 was administered at the dosage of 3 mg/Kg at the weeks 0 , 2 and 6 and then every 8 weeks . RESULTS : About half patients ameliorated in agreement with both P10323 20 criteria and DAS28 evaluation . The clinical improvement was accompanied by a reduction of the steroid daily dosage . No relevant side effects were observed . CONCLUSION : DB00065 is effective in a significant number of patients with severe rheumatoid arthritis , with a good tolerability .